6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $10M | -$130M | 0.0% | -1315.4% | -$140M | $33M | $152M |
| 2024 | $3M | -$127M | 0.0% | -4787.7% | -$115M | $32M | $179M |
| 2023 | $21M | -$89M | 0.0% | -444.0% | -$65M | $30M | $133M |
| 2022 | $14M | -$66M | 0.0% | -492.3% | -$71M | $29M | $120M |
| 2021 | $10M | -$49M | 0.0% | -479.6% | -$59M | — | $161M |
| 2020 | $1M | -$26M | 0.0% | -2417.8% | -$7M | — | $35M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $982000 | -$29M | 0.0% | -2967.3% | -$24M | $33M | $128M |
| Dec '25 | $3M | -$23M | 0.0% | -929.4% | -$32M | $33M | $152M |
| Sep '25 | $3M | -$36M | 0.0% | -1475.6% | -$34M | $32M | $170M |
| Jun '25 | $3M | -$37M | 0.0% | -1256.6% | -$35M | $32M | $169M |
| Mar '25 | $2M | -$34M | 0.0% | -1669.7% | -$39M | $32M | $154M |
| Dec '24 | $665000 | -$36M | 0.0% | -5520.6% | -$28M | $32M | $179M |
| Sep '24 | $1M | -$30M | 0.0% | -3109.8% | -$29M | $31M | $133M |
| Jun '24 | $536000 | -$32M | 0.0% | -6364.6% | -$27M | $30M | $242M |
| Mar '24 | $566000 | -$30M | 0.0% | -5542.9% | -$30M | $30M | $141M |
| Dec '23 | $7M | -$20M | 0.0% | -296.2% | -$24M | $30M | $133M |
| Sep '23 | $4M | -$23M | 0.0% | -636.7% | $7M | $30M | $155M |
| Jun '23 | $3M | -$24M | 0.0% | -781.8% | -$22M | $30M | $209M |
| Mar '23 | $7M | -$23M | 0.0% | -334.3% | -$24M | $30M | $96M |
| Dec '22 | $3M | -$19M | 0.0% | -602.6% | -$17M | $29M | $120M |
| Sep '22 | $3M | -$16M | 0.0% | -493.0% | -$17M | $29M | $137M |
| Jun '22 | $4M | -$15M | 0.0% | -375.9% | -$15M | — | $126M |
| Mar '22 | $3M | -$16M | 0.0% | -535.0% | -$21M | — | $141M |
| Dec '21 | $3M | -$14M | 0.0% | -497.6% | -$17M | — | $161M |
| Sep '21 | $2M | -$16M | 0.0% | -656.8% | -$14M | — | $182M |
| Jun '21 | $3M | -$11M | 0.0% | -375.0% | -$15M | — | $106M |
How the market has priced TCRX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, TScan Therapeutics, Inc.'s revenue has grown 56.9% per year. These are computed facts, not advice.
As of FY2025, TScan Therapeutics, Inc. reported $33M of total debt against $152M of cash; operating income covered interest expense -49.0×.
In FY2025, gross margin was —, operating margin -1315.4%, and net margin -1256.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.